News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,577 Results
Type
Article (13796)
Company Profile (101)
Press Release (251680)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88054)
Career Advice (465)
Deals (15343)
Drug Delivery (67)
Drug Development (36607)
Employer Resources (49)
FDA (6294)
Job Trends (6200)
News (150236)
Policy (14039)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (32)
Alliances (23224)
ALS (36)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (38)
Approvals (6330)
Artificial intelligence (106)
Autoimmune disease (9)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (20)
Brain cancer (16)
Breast cancer (78)
Cancer (602)
Cardiovascular disease (71)
Career advice (407)
Career pathing (11)
CAR-T (22)
Cell therapy (87)
Cervical cancer (4)
Clinical research (30911)
Collaboration (336)
Compensation (152)
Complete response letters (17)
COVID-19 (757)
CRISPR (20)
C-suite (121)
Cystic fibrosis (37)
Data (625)
Denatured (15)
Depression (9)
Diabetes (78)
Diagnostics (1317)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (60)
Drug pricing (64)
Drug shortages (12)
Duchenne muscular dystrophy (36)
Earnings (32113)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37458)
Executive appointments (383)
FDA (6709)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (209)
Gene editing (38)
Generative AI (9)
Gene therapy (100)
GLP-1 (347)
Government (1298)
Grass and pollen (2)
Guidances (16)
Healthcare (3564)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (34)
Indications (12)
Infectious disease (792)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (47)
Interviews (59)
IPO (5875)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (11)
Layoffs (180)
Leadership (3)
Legal (3433)
Liver cancer (19)
Lung cancer (80)
Lymphoma (53)
Machine learning (1)
Management (16)
Manufacturing (151)
MASH (32)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9673)
Metabolic disorders (257)
Multiple sclerosis (20)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (6)
Neuroscience (574)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (702)
Now hiring (7)
Obesity (147)
Opinion (119)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (46)
Partnered (7)
Patents (115)
Patient recruitment (28)
Peanut (10)
People (28935)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8043)
Phase II (13077)
Phase III (11737)
Pipeline (437)
Policy (70)
Postmarket research (1401)
Preclinical (3214)
Press Release (25)
Prostate cancer (46)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (167)
Real estate (2637)
Recruiting (17)
Regulatory (10107)
Reports (14)
Research institute (565)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (36)
Series A (36)
Series B (12)
Service/supplier (3)
Sickle cell disease (32)
Southern California (715)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1628)
State (2)
Stomach cancer (3)
Supply chain (31)
Tariffs (21)
The Weekly (30)
United States (7131)
Vaccines (152)
Venture capitalists (14)
Weight loss (99)
Women's health (8)
Worklife (3)
Date
Last 7 days (175)
Last 30 days (770)
Last 365 days (11790)
2025 (3437)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (55)
Arkansas (3)
Asia (20112)
Australia (2612)
California (1701)
Canada (901)
China (235)
Colorado (66)
Connecticut (67)
Delaware (54)
Europe (39422)
Florida (322)
Georgia (38)
Idaho (9)
Illinois (195)
India (16)
Indiana (133)
Iowa (1)
Japan (91)
Kansas (57)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (252)
Massachusetts (1469)
Michigan (30)
Minnesota (93)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (761)
New Mexico (7)
New York (499)
North Carolina (386)
North Dakota (2)
Northern California (702)
Ohio (49)
Oklahoma (4)
Oregon (16)
Pennsylvania (436)
Puerto Rico (8)
Rhode Island (9)
South America (502)
South Carolina (2)
Southern California (715)
Tennessee (34)
Texas (227)
Utah (33)
Virginia (72)
Washington D.C. (31)
Washington State (116)
Wisconsin (15)
265,577 Results for "centessa pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Centessa’s Narcolepsy Drug Shows ‘Compelling’ Effect in Early Study
Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting the company in a strong position in the $15 billion market.
April 7, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024
March 25, 2025
·
13 min read
Press Releases
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - January 28, 2025
January 29, 2025
·
1 min read
Genetown
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Nxera Pharma announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuticals pursuant to a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 agonist, ORX750.
May 30, 2024
·
2 min read
Genetown
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - May 21, 2024
Centessa Pharmaceuticals plc today announced that members of its management team will participate in the following investor conferences.
May 21, 2024
·
1 min read
Press Releases
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
January 9, 2025
·
7 min read
Press Releases
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
November 5, 2024
·
1 min read
Press Releases
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
March 6, 2025
·
1 min read
Business
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2024.
May 13, 2024
·
13 min read
Genetown
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals plc announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares, each representing one ordinary share.
April 23, 2024
·
3 min read
1 of 26,558
Next
